Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613910 · ClinicalTrials.gov registry record · Phase 3
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT02613910 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 1 participants.
The verdict
NCT02613910, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who complete the OPV116910 trial in order to obtain further long term safety and tolerability information in subjects with pemphigus vulgaris receiving ofatumumab SC every 4 weeks (wk).
Interventions
- DRUG Acetaminophen/paracetamol
- DRUG Prednisone/Prednisolone
- DRUG Ofatumumab
- DRUG Antihistamine (cetirizine or equivalent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-12-23 |
| Est. Completion | 2016-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613910
The ClinicalTrials.gov registry entry for NCT02613910 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Acetaminophen/paracetamol is the first listed.
NCT02613910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02613910 about?
NCT02613910 is a clinical study titled "Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris". This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who complete the OPV116910 trial in order to obtain further long term safety and ...
What is the current status of trial NCT02613910?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2015-12-23. Estimated completion is 2016-03-23.
What interventions are being tested in trial NCT02613910?
The interventions under investigation include: Acetaminophen/paracetamol (DRUG), Prednisone/Prednisolone (DRUG), Ofatumumab (DRUG), Antihistamine (cetirizine or equivalent) (DRUG).
Who is sponsoring clinical trial NCT02613910?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.